Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 8 | 13 |
| 1996 | 0 | 4 | 4 |
| 1997 | 2 | 3 | 5 |
| 1998 | 0 | 8 | 8 |
| 1999 | 2 | 5 | 7 |
| 2000 | 3 | 1 | 4 |
| 2001 | 2 | 3 | 5 |
| 2002 | 4 | 5 | 9 |
| 2003 | 3 | 6 | 9 |
| 2004 | 5 | 11 | 16 |
| 2005 | 13 | 21 | 34 |
| 2006 | 21 | 33 | 54 |
| 2007 | 29 | 42 | 71 |
| 2008 | 23 | 45 | 68 |
| 2009 | 47 | 44 | 91 |
| 2010 | 64 | 49 | 113 |
| 2011 | 67 | 55 | 122 |
| 2012 | 69 | 62 | 131 |
| 2013 | 83 | 66 | 149 |
| 2014 | 109 | 69 | 178 |
| 2015 | 86 | 53 | 139 |
| 2016 | 93 | 45 | 138 |
| 2017 | 93 | 53 | 146 |
| 2018 | 87 | 53 | 140 |
| 2019 | 105 | 56 | 161 |
| 2020 | 70 | 69 | 139 |
| 2021 | 59 | 55 | 114 |
| 2022 | 17 | 90 | 107 |
| 2023 | 8 | 73 | 81 |
| 2024 | 40 | 72 | 112 |
| 2025 | 17 | 6 | 23 |
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Navigating Ongoing Challenges in GI Stromal Tumors. Am Soc Clin Oncol Educ Book. 2025 06; 45(3):e473224.
-
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Cancer Res Commun. 2025 May 01; 5(5):767-773.
-
A small molecule PKCε inhibitor reduces hyperalgesia induced by paclitaxel or opioid withdrawal. JCI Insight. 2025 Apr 22; 10(8).
-
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer. 2025 May; 203:108551.
-
Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2- Metastatic Breast Cancer. Cancer Med. 2025 Apr; 14(7):e70719.
-
A computational journey in anticancer drug discovery: Exploring AKT1 inhibition by novel oxadiazoles using molecular docking, ADMET, density functional theory and molecular dynamic simulation. Comput Biol Chem. 2025 Aug; 117:108425.
-
Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer Cell. 2025 Apr 14; 43(4):740-756.e8.
-
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer Cell. 2025 Mar 10; 43(3):428-445.e6.
-
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. Blood Adv. 2025 Feb 25; 9(4):722-728.
-
Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I]Radioiodinated DYRK1A Inhibitor. Molecules. 2025 Feb 21; 30(5).